HC Wainwright Analysts Lift Earnings Estimates for Anixa Biosciences, Inc. (NASDAQ:ANIX)

Anixa Biosciences, Inc. (NASDAQ:ANIX) – Equities research analysts at HC Wainwright lifted their FY2024 EPS estimates for shares of Anixa Biosciences in a research note issued on Monday, September 16th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.42) per share for the year, up from their previous estimate of ($0.43). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Anixa Biosciences’ current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Anixa Biosciences’ Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.46) EPS.

Separately, EF Hutton Acquisition Co. I raised Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th.

Anixa Biosciences Trading Up 0.3 %

Anixa Biosciences stock opened at $3.45 on Wednesday. Anixa Biosciences has a 1 year low of $2.14 and a 1 year high of $5.13. The company has a market cap of $110.42 million, a PE ratio of -9.32 and a beta of 0.86. The company’s 50-day moving average is $3.14 and its two-hundred day moving average is $2.99.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings results on Friday, September 6th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Concorde Asset Management LLC bought a new position in Anixa Biosciences in the second quarter valued at about $31,000. Staley Capital Advisers Inc. bought a new position in Anixa Biosciences in the first quarter valued at about $31,000. Simplicity Wealth LLC bought a new position in Anixa Biosciences in the first quarter valued at about $44,000. Nations Financial Group Inc. IA ADV grew its position in Anixa Biosciences by 50.0% in the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after acquiring an additional 7,500 shares during the last quarter. Finally, Virtu Financial LLC grew its position in Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after acquiring an additional 5,183 shares during the last quarter. Institutional investors own 29.13% of the company’s stock.

Insider Transactions at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. purchased 21,646 shares of the business’s stock in a transaction on Tuesday, July 30th. The stock was acquired at an average price of $3.06 per share, with a total value of $66,236.76. Following the acquisition, the director now directly owns 890,754 shares of the company’s stock, valued at approximately $2,725,707.24. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 22.60% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.